March 08, 2019
1 min read
Save

FDA accepts NDA for pretomanid in combination TB regimen

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

TB Alliance announced that the FDA has accepted a new drug application for its novel tuberculosis drug candidate, pretomanid, as part of a drug regimen used to treat extensively drug-resistant TB; treatment-intolerant, multidrug-resistant TB; and treatment-nonresponsive, multidrug-resistant TB.

Pretomanid, a member of a class of compounds known as nitroimidozooxazines, would be used in combination with bedaquiline and linezolid. It has been studied in 20 clinical trials alone and in combination with other anti-TB drugs and has been administered in a clinical trial setting to more than 1,200 people in 14 countries, according to TB Alliance.

The regimen of bedaquiline, pretomanid and linezolid (BPaL) was first studied clinically in the phase 3 Nix-TB trial in South Africa. Researchers enrolled patients aged 14 years and older (mean age, 35.2 years) with extensively drug-resistant TB and treatment-intolerant or nonresponsive multidrug-resistant TB. Patients were treated with BPaL for 6 months, which was extendable to 9 months, with intent to cure.

According to a modified intent-to-treat analysis of interim results of the first 75 patients, 89% of study participants had a favorable outcome, with their clinical infection resolved and sputum cultures negative for TB after 6 months of treatment and 6 months of post-treatment follow-up.

The FDA granted priority review of the NDA, with a Prescription Drug User Fee Act action date expected in the third quarter of 2019, according to TB Alliance.

References:

Conradie F, et al. Abstract OA03-213-25. Presented at: The Union World Conference on Lung Health; October 24-27, 2018; The Hague, the Netherlands.

Conradie F, et al. Abstract 80LB. Presented at: Conference on Retroviruses and Opportunistic Infections; Feb. 13-16, 2017; Seattle.